Nanosuspensions in drug delivery.
A surprisingly large proportion of new drug candidates emerging from drug discovery programmes are water insoluble, and therefore poorly bioavailable, leading to abandoned development efforts. These so-called 'brickdust' candidates can now be rescued by formulating them into crystalline nanosuspensions. In the process of overcoming issues involving solubility, additional pharmacokinetic benefits of the drugs so formulated have come to be appreciated. As such, insolubility issues of the past have provoked a paradigm change, which now offers novel solutions for innovative drugs of the future.
Rabinow
Barrett E
BE
Strategic Technical Development, Baxter Healthcare Corporation, Baxter Technology Park, Round Lake, Illinois 60073, USA. barrett_rabinow@baxter.com
D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000639:trends*; D004339:Drug Compounding; D004345:Drug Industry; D006801:Humans; D008863:Microspheres; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D010599:Pharmacokinetics; D013535:Suspensions
D004364:Pharmaceutical Preparations; D013535:Suspensions